LCTX Company Profile and Key Details
Lineage Cell Therapeutics, Inc.
LCTX Stock Price Chart
Stock Price Today
Lineage Cell Therapeutics, Inc. (LCTX) stock declined over -4.29%, trading at $0.66 on AMEX, down from the previous close of $0.69. The stock opened at $0.69, fluctuating between $0.64 and $0.72 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Company Information
| Employees | 68 |
| Beta | 1.28 |
| Sales or Revenue | $8.95M |
| 5Y Sales Change% | 3.643% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Lineage Cell Therapeutics, Inc. (AMEX: LCTX) stock price is $0.66 in the last trading session. During the trading session, LCTX stock reached the peak price of $0.72 while $0.64 was the lowest point it dropped to. The percentage change in LCTX stock occurred in the recent session was -4.29% while the dollar amount for the price change in LCTX stock was -$0.03.
The AMEX listed LCTX is part of Biotechnology industry that operates in the broader Healthcare sector. Lineage Cell Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. William Annett MBA
Pres & Chief Executive Officer of OncoCyte Corporation
Mr. George A. Samuel III, J.D.
Gen. Counsel & Company Sec.
Dr. Rami Skaliter
Chief Executive Officer of Cell Cure Neurosciences Ltd.
Mr. Brian M. Culley M.A., M.B.A.
Chief Executive Officer, Pres & Director
Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D.
Senior Vice President of Clinical & Medical Affairs
Ms. Alexandra Hernandez
Senior Director of Fin. & Controller
Dr. Harold D. Waitz
Vice President of Regulatory Affairs & Quality Control
Ms. Jill Ann Howe
Chief Financial Officer & Principal Financial and Accounting Officer
Ioana C. Hone
Director of Investor Relations
LCTX's closing price is 37.48% higher than its 52-week low of $0.48 where as its distance from 52-week high of $1.61 is -59.01%.
Number of LCTX employees currently stands at 68.
Official Website of LCTX is: https://www.lineagecell.com
LCTX could be contacted at phone 442 287 8990 and can also be accessed through its website. LCTX operates from 2173 Salk Avenue, Carlsbad, CA 92008, United States.
LCTX stock volume for the day was 1.67M shares. The average number of LCTX shares traded daily for last 3 months was 2.67M.
The market value of LCTX currently stands at $145.45M with its latest stock price at $0.66 and 220.42M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com